Contineum Therapeutics (CTNM) said Monday the US Food and Drug Administration approved its investigational new drug application for PIPE-791 to treat chronic pain related to osteoarthritis and low back pain.
The phase 1b trial to potentially treat the two indications is expected to start in Q1 2025, the company said, adding it expects to enroll about 40 people at up to five sites.
Topline results from the trial are expected in early 2026, Contineum said.
Price: 16.50, Change: -0.71, Percent Change: -4.13
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.